bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure 2 from Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer
Authors: Gross Matt I. , Demo Susan D. , Dennison Jennifer B. , Chen Lijing , Chernov-Rogan Tania , Goyal Bindu , Janes Julie R. , Laidig Guy J. , Lewis Evan R. , Li Jim , MacKinnon Andrew L. , Parlati Francesco , Rodriguez Mirna L.M. , Shwonek Peter J. , Sjogren Eric B. , Stanton Timothy F. , Wang Taotao , Yang Jinfu , Zhao Frances , Bennett Mark K.
Published: April 2023

PDF - 189K, Supplementary Figure S2. CB-839 has potent anti-proliferative activity in TNBC cells that is associated with selective impairment of glutamine utilization.
Supplementary Figure Legend from Polo-like Kinase Inhibitor Ro5203280 Has Potent Antitumor Activity in Nasopharyngeal Carcinoma
Authors: Cheung Arthur Kwok Leung , Yan Ip Joseph Chok , Lung Hong Lok , Wu Jim Zhen , Tsao Sai Wah , Lung Maria Li
Published: April 2023

PDF file - 90K
Supplementary Figure 3 from XPO1 (CRM1) Inhibition Represses STAT3 Activation to Drive a Survivin-Dependent Oncogenic Switch in Triple-Negative Breast Cancer
Authors: Cheng Yan , Holloway Michael P. , Nguyen Kevin , McCauley Dilara , Landesman Yosef , Kauffman Michael G. , Shacham Sharon , Altura Rachel A.
Published: April 2023

PDF file - 87K, Survivin protein levels normalized to tubulin.
Supplementary Figure 1 from XPO1 (CRM1) Inhibition Represses STAT3 Activation to Drive a Survivin-Dependent Oncogenic Switch in Triple-Negative Breast Cancer
Authors: Cheng Yan , Holloway Michael P. , Nguyen Kevin , McCauley Dilara , Landesman Yosef , Kauffman Michael G. , Shacham Sharon , Altura Rachel A.
Published: April 2023

PDF file - 66K, Molecular structures of the KPT-SINES.
Supplementary Figures 1 - 4 from Antitumor Activity of 7-Aminocarboxycoumarin Derivatives, a New Class of Potent Inhibitors of Lactate Influx but Not Efflux
Authors: Draoui Nihed , Schicke Olivier , Seront Emmanuel , Bouzin Caroline , Sonveaux Pierre , Riant Olivier , Feron Olivier
Published: April 2023

PDF file - 276KB, Supplementary Figure 1. Chemical structures of 7ACC, 3BP and AR-C155858. Supplementary Figure 2. Effects of 7ACC on FaDu cell viability. Supplementary Figure 3. Pimonidazole labelling of tumor sections from control and 7ACC2-treated mice. Supplementary Figure 4. Effects of 3BP on lactate uptake and titration of the effects of 7ACC by extracellular lactate.
Supplementary Table 1 from Contribution of Hepatic Organic Anion-Transporting Polypeptides to Docetaxel Uptake and Clearance
Authors: Lee Hannah H. , Leake Brenda F. , Teft Wendy , Tirona Rommel G. , Kim Richard B. , Ho Richard H.
Published: April 2023

SLCO1B1 Variants
Supplementary Figure Legends from Overcoming Acquired BRAF Inhibitor Resistance in Melanoma via Targeted Inhibition of Hsp90 with Ganetespib
Authors: Acquaviva Jaime , Smith Donald L. , Jimenez John-Paul , Zhang Chaohua , Sequeira Manuel , He Suqin , Sang Jim , Bates Richard C. , Proia David A.
Published: April 2023

PDF file - 65K
Supplementary Figure S3 from S49076 Is a Novel Kinase Inhibitor of MET, AXL, and FGFR with Strong Preclinical Activity Alone and in Association with Bevacizumab
Authors: Burbridge Mike F. , Bossard Céline J. , Saunier Carine , Fejes Imre , Bruno Alain , Léonce Stéphane , Ferry Gilles , Da Violante Georges , Bouzom François , Cattan Valérie , Jacquet-Bescond Anne , Comoglio Paolo M. , Lockhart Brian P. , Boutin Jean A. , Cordi Alex , Ortuno Jean-Claude , Pierré Alain , Hickman John A. , Cruzalegui Francisco H. , Depil Stéphane
Published: April 2023

GAS6-mediated activation of AKT in MDA-MB-231 cells is dependent on AXL
Supplementary Figure S2 from S49076 Is a Novel Kinase Inhibitor of MET, AXL, and FGFR with Strong Preclinical Activity Alone and in Association with Bevacizumab
Authors: Burbridge Mike F. , Bossard Céline J. , Saunier Carine , Fejes Imre , Bruno Alain , Léonce Stéphane , Ferry Gilles , Da Violante Georges , Bouzom François , Cattan Valérie , Jacquet-Bescond Anne , Comoglio Paolo M. , Lockhart Brian P. , Boutin Jean A. , Cordi Alex , Ortuno Jean-Claude , Pierré Alain , Hickman John A. , Cruzalegui Francisco H. , Depil Stéphane
Published: April 2023

Kinase interaction map for S49076 at 100 nM
Supplementary Figure 2 from Overcoming Acquired BRAF Inhibitor Resistance in Melanoma via Targeted Inhibition of Hsp90 with Ganetespib
Authors: Acquaviva Jaime , Smith Donald L. , Jimenez John-Paul , Zhang Chaohua , Sequeira Manuel , He Suqin , Sang Jim , Bates Richard C. , Proia David A.
Published: April 2023

PDF file - 441K, Ganetespib activity in A375 melanoma xenografts.
Supplementary Figure Legends from S49076 Is a Novel Kinase Inhibitor of MET, AXL, and FGFR with Strong Preclinical Activity Alone and in Association with Bevacizumab
Authors: Burbridge Mike F. , Bossard Céline J. , Saunier Carine , Fejes Imre , Bruno Alain , Léonce Stéphane , Ferry Gilles , Da Violante Georges , Bouzom François , Cattan Valérie , Jacquet-Bescond Anne , Comoglio Paolo M. , Lockhart Brian P. , Boutin Jean A. , Cordi Alex , Ortuno Jean-Claude , Pierré Alain , Hickman John A. , Cruzalegui Francisco H. , Depil Stéphane
Published: April 2023

Supplementary Figure Legends
Supplementary Figure 2 from Nuclear Translocation of Hand-1 Acts as a Molecular Switch to Regulate Vascular Radiosensitivity in Medulloblastoma Tumors: The Protein uPAR Is a Cytoplasmic Sequestration Factor for Hand-1
Authors: Asuthkar Swapna , Gogineni Venkateswara Rao , Rao Jasti S. , Velpula Kiran Kumar
Published: April 2023

PDF file - 2038K, Supplementary Fig.2. Hand-1-mediated negative regulation of HIF-1A.
Supplementary Figures 1 - 5, Table 1 from Inhibition of Wee1, AKT, and CDK4 Underlies the Efficacy of the HSP90 Inhibitor XL888 in an In Vivo Model of NRAS-Mutant Melanoma
Authors: Haarberg H. Eirik , Paraiso Kim H.T. , Wood Elizabeth , Rebecca Vito W. , Sondak Vernon K. , Koomen John M. , Smalley Keiran S.M.
Published: April 2023

PDF file - 295K, Supplemental Figure 1: XL888 (0.3 μM) treatment induces the nuclear accumulation of FOXO3a. Supplemental Figure 2: XL888 decreases Mcl-1 mRNA expression in NRAS mutant melanoma. Supplemental Figure 3: BAK is not required for XL888-mediated apoptosis. Supplemental Figure 4: The BH3 family protein inhibitor ABT-737 enhances the pro-apoptotic effects of XL888 in the WM1366 and WM1361A cell lines. Supplemental Figure 5: The effects of XL888 (300nM) and ABT-737 (1 μM) on the viability of NRAS mutant melanoma spheroids. Supplemental Table 1: List of heat shock proteins used on the LC-MRM by UniPROT ID and gene name.
Supplementary Figure 1 from Nuclear Translocation of Hand-1 Acts as a Molecular Switch to Regulate Vascular Radiosensitivity in Medulloblastoma Tumors: The Protein uPAR Is a Cytoplasmic Sequestration Factor for Hand-1
Authors: Asuthkar Swapna , Gogineni Venkateswara Rao , Rao Jasti S. , Velpula Kiran Kumar
Published: April 2023

PDF file - 1829K, Supplementary Fig.1. Negative regulation of Hand-1 in cancer stemness.
Supplementary Figures 1 - 9, Tables 1 - 2 from RAD51C-Deficient Cancer Cells Are Highly Sensitive to the PARP Inhibitor Olaparib
Authors: Min Ahrum , Im Seock-Ah , Yoon Young-Kwang , Song Sang-Hyun , Nam Hyun-Jin , Hur Hyung-Seok , Kim Hwang-Phill , Lee Kyung-Hun , Han Sae-Won , Oh Do-Youn , Kim Tae-You , O'Connor Mark J. , Kim Woo-Ho , Bang Yung-Jue
Published: April 2023

PDF file - 3250K, Figure S1 Olaparib has variable levels of anti-tumor activity in human cancer cell lines. Figure S2 Olaparib sensitive cell lines have different patterns of gene expression compared to insensitive cell lines. Figure S3 PTEN expression does not affect olaparib sensitivity. Figure S4 RAD51C expression affects olaparib sensitivity in human cancer cell lines. Figure S5 RAD51C over-expression decreases sensitivity to olaparib in the BT-549 cell line. Figure S6 Olaparib induces G2/M cell cycle arrest and apoptosis in sensitive cell lines. Figure S7 RAD51C depletion increases the accumulation of DNA damage. Figure S8 RAD51C expression decreases in tumor tissues. Figure S9 RAD51C expression is down-regulated in gastric tumor tissues via DNA methylation. Table S1. Sequences of the primers for PCR and real-time PCR analyses. Table S2. BRCA1 and BRCA2 mutations in the gastric cancer cell lines.
Supplementary Table 1 - 2 from Tirapazamine Sensitizes Hepatocellular Carcinoma Cells to Topoisomerase I Inhibitors via Cooperative Modulation of Hypoxia-Inducible Factor-1α
Authors: Cai Tian-Yu , Liu Xiao-Wen , Zhu Hong , Cao Ji , Zhang Jun , Ding Ling , Lou Jian-Shu , He Qiao-Jun , Yang Bo
Published: April 2023

PDF file - 135K, Supplementary Table S1. CI Values of SN-38 at Concentrations Applied in Combination with Tirapazamine in Different Liver Cell Lines; Supplementary Table S2. In Vivo Efficacy of CPT-11 in Combination with Tirapazamine; and supplementary figure legends.
Supplementary Figure 5 from Tirapazamine Sensitizes Hepatocellular Carcinoma Cells to Topoisomerase I Inhibitors via Cooperative Modulation of Hypoxia-Inducible Factor-1α
Authors: Cai Tian-Yu , Liu Xiao-Wen , Zhu Hong , Cao Ji , Zhang Jun , Ding Ling , Lou Jian-Shu , He Qiao-Jun , Yang Bo
Published: April 2023

PDF file - 59K, Figure S5. Overexpression of HIF-1alpha is associated with resistance to topoisomerase I inhibitors in HCC cells.
Supplementary Figure 4 from Tirapazamine Sensitizes Hepatocellular Carcinoma Cells to Topoisomerase I Inhibitors via Cooperative Modulation of Hypoxia-Inducible Factor-1α
Authors: Cai Tian-Yu , Liu Xiao-Wen , Zhu Hong , Cao Ji , Zhang Jun , Ding Ling , Lou Jian-Shu , He Qiao-Jun , Yang Bo
Published: April 2023

PDF file - 131K, Figure S4. TPZ and SN-38 decrease the rate of HIF-1alpha protein synthesis.
Supplementary Figure S3 from Preclinical Evaluation of Transcriptional Targeting Strategy for Human Hepatocellular Carcinoma in an Orthotopic Xenograft Mouse Model
Authors: Sia Kian Chuan , Huynh Hung , Chung Alexander Yaw Fui , Ooi London Lucien Peng Jin , Lim Kiat Hon , Hui Kam Man , Lam Paula Yeng Po
Published: April 2023

Supplementary Figure S3 - PDF file 108K, Cell cycle analysis on deltaGli36, A549, HuH-7 and PLC/PRF/5 cells
Supplementary Figure S2 from Preclinical Evaluation of Transcriptional Targeting Strategy for Human Hepatocellular Carcinoma in an Orthotopic Xenograft Mouse Model
Authors: Sia Kian Chuan , Huynh Hung , Chung Alexander Yaw Fui , Ooi London Lucien Peng Jin , Lim Kiat Hon , Hui Kam Man , Lam Paula Yeng Po
Published: April 2023

Supplementary Figure S2 - PDF file 104K, Cell cycle-dependent gene expression of AH-6CC-L2C in proliferating orthotopic PLC/PRF/5-DsRed2 tumors versus non-proliferating quiescent normal liver cells in SCID mice. A, Cell cycle analysis of primary cells isolated from normal liver of control SCID mouse versus orthotopically implanted PLC/PRF/5-DsRed2 tumors in left lateral liver lobe of SCID mouse. B, Non-invasive imaging of luciferase gene expression of mice after 24 h post intrahepatic or intratumoral injection of 3 � 106 TU of AH-6CC-L2C into left lateral liver lobes or PLC/PRF/5-DsRed2 tumors, respectively. The injection sites were indicated by an asterisk (*). Non-invasive imaging of DsRed2 signal and the white line indicated the PLC/PRF/5-DsRed2 tumor region. C, Corresponding quantification of total flux emitted from the injection sites (left panel). Corresponding luciferase assays on normal livers and PLC/PRF/5-DsRed2 tumors harvested from SCID mice after 24 h post injection (right panel). All data were presented as mean plus-minus SEM, n = 3
Supplementary Figure 1 from Tirapazamine Sensitizes Hepatocellular Carcinoma Cells to Topoisomerase I Inhibitors via Cooperative Modulation of Hypoxia-Inducible Factor-1α
Authors: Cai Tian-Yu , Liu Xiao-Wen , Zhu Hong , Cao Ji , Zhang Jun , Ding Ling , Lou Jian-Shu , He Qiao-Jun , Yang Bo
Published: April 2023

PDF file - 159K, Figure S1. Depletion of HIF-1alpha could reverse hypoxia-induced resistance to topoisomerase I inhibitors.
Supplementary Table 3 from Chemogenetic Evaluation of the Mitotic Kinesin CENP-E Reveals a Critical Role in Triple-Negative Breast Cancer
Authors: Kung Pei-Pei , Martinez Ricardo , Zhu Zhou , Zager Michael , Blasina Alessandra , Rymer Isha , Hallin Jill , Xu Meirong , Carroll Christopher , Chionis John , Wells Peter , Kozminski Kirk , Fan Jeffery , Guicherit Oivin , Huang Buwen , Cui Mei , Liu Chaoting , Huang Zhongdong , Sistla Anand , Yang Jennifer , Murray Brion W.
Published: April 2023

PDF - 76K, Cell cycle analysis of PF-2771 treatment of MDA-MB-468 tumor cells.
Supplementary Materials and Methods from Chemogenetic Evaluation of the Mitotic Kinesin CENP-E Reveals a Critical Role in Triple-Negative Breast Cancer
Authors: Kung Pei-Pei , Martinez Ricardo , Zhu Zhou , Zager Michael , Blasina Alessandra , Rymer Isha , Hallin Jill , Xu Meirong , Carroll Christopher , Chionis John , Wells Peter , Kozminski Kirk , Fan Jeffery , Guicherit Oivin , Huang Buwen , Cui Mei , Liu Chaoting , Huang Zhongdong , Sistla Anand , Yang Jennifer , Murray Brion W.
Published: April 2023

PDF - 238K, Supplementary Materials and Methods
Supplementary Figure 4 from Chemogenetic Evaluation of the Mitotic Kinesin CENP-E Reveals a Critical Role in Triple-Negative Breast Cancer
Authors: Kung Pei-Pei , Martinez Ricardo , Zhu Zhou , Zager Michael , Blasina Alessandra , Rymer Isha , Hallin Jill , Xu Meirong , Carroll Christopher , Chionis John , Wells Peter , Kozminski Kirk , Fan Jeffery , Guicherit Oivin , Huang Buwen , Cui Mei , Liu Chaoting , Huang Zhongdong , Sistla Anand , Yang Jennifer , Murray Brion W.
Published: April 2023

PDF - 219K, PK/PD/Efficacy model analysis.
Supplementary Figure 3 from Chemogenetic Evaluation of the Mitotic Kinesin CENP-E Reveals a Critical Role in Triple-Negative Breast Cancer
Authors: Kung Pei-Pei , Martinez Ricardo , Zhu Zhou , Zager Michael , Blasina Alessandra , Rymer Isha , Hallin Jill , Xu Meirong , Carroll Christopher , Chionis John , Wells Peter , Kozminski Kirk , Fan Jeffery , Guicherit Oivin , Huang Buwen , Cui Mei , Liu Chaoting , Huang Zhongdong , Sistla Anand , Yang Jennifer , Murray Brion W.
Published: April 2023

PDf - 114K, Analysis of mouse body weight in the tumor growth models.
Supplementary Table 1 from Targeting Multiple Key Signaling Pathways in Melanoma Using Leelamine
Authors: Gowda Raghavendra , Madhunapantula SubbaRao V. , Kuzu Omer F. , Sharma Arati , Robertson Gavin P.
Published: April 2023

PDF - 73K, Pathway or protein expression or activity not regulated by leelamine in melanoma cells.
Supplementary Figure Legends from Targeting Multiple Key Signaling Pathways in Melanoma Using Leelamine
Authors: Gowda Raghavendra , Madhunapantula SubbaRao V. , Kuzu Omer F. , Sharma Arati , Robertson Gavin P.
Published: April 2023

PDF - 57K, Legends to Supplementary Figures.
Supplementary Figure 4 from Targeting Multiple Key Signaling Pathways in Melanoma Using Leelamine
Authors: Gowda Raghavendra , Madhunapantula SubbaRao V. , Kuzu Omer F. , Sharma Arati , Robertson Gavin P.
Published: April 2023

PDF - 72K, Phospho ERK1/2 levels did not change in UACC 903 xenograft following leelamine treatment.
Supplementary Figure 2 from Targeting Multiple Key Signaling Pathways in Melanoma Using Leelamine
Authors: Gowda Raghavendra , Madhunapantula SubbaRao V. , Kuzu Omer F. , Sharma Arati , Robertson Gavin P.
Published: April 2023

PDF - 66K, Leelamine inhibits Stat3 pathway in melanoma cells.
Supplementary Table 3 from KRAS Mutation Status Is Associated with Enhanced Dependency on Folate Metabolism Pathways in Non–Small Cell Lung Cancer Cells
Authors: Moran Diarmuid M. , Trusk Patricia B. , Pry Karen , Paz Keren , Sidransky David , Bacus Sarah S.
Published: April 2023

PDF - 69K, Normalized basal gene expression microarray data for non-squamous NSCLC NCI60 cell lines were grouped according to KRAS mutation status. Genes showing significant differences in expression between KRAS mutant and KRAS wildtype cells were analyzed using Ingenuity Pathway Analysis (IPA) and genes predicted to be regulated by MYC were identified.
Supplementary Table 2 from KRAS Mutation Status Is Associated with Enhanced Dependency on Folate Metabolism Pathways in Non–Small Cell Lung Cancer Cells
Authors: Moran Diarmuid M. , Trusk Patricia B. , Pry Karen , Paz Keren , Sidransky David , Bacus Sarah S.
Published: April 2023

PDF - 68K, Normalized basal gene expression microarray data for non-squamous NSCLC NCI60 cell lines were grouped according to KRAS mutation status. Genes showing significant differences in expression between KRAS mutant and KRAS wildtype cells were analyzed using Ingenuity Pathway Analysis (IPA) and significantly different upstream regulators were predicted.
Supplementary Table 1 from KRAS Mutation Status Is Associated with Enhanced Dependency on Folate Metabolism Pathways in Non–Small Cell Lung Cancer Cells
Authors: Moran Diarmuid M. , Trusk Patricia B. , Pry Karen , Paz Keren , Sidransky David , Bacus Sarah S.
Published: April 2023

PDF - 75K, Normalized basal gene expression microarray data for non-squamous NSCLC NCI60 cell lines were grouped according to KRAS mutation status. Genes showing significant differences in expression between KRAS mutant and KRAS wildtype cells were analyzed using Ingenuity Pathway Analysis (IPA) and significantly different canonical pathways were identified.
Supplementary Figure 5 from A Novel Inhibitor of c-Met and VEGF Receptor Tyrosine Kinases with a Broad Spectrum of In Vivo Antitumor Activities
Authors: Awazu Yoshiko , Nakamura Kazuhide , Mizutani Akio , Kakoi Yuichi , Iwata Hidehisa , Yamasaki Seiji , Miyamoto Naoki , Imamura Shinichi , Miki Hiroshi , Hori Akira
Published: April 2023

PDF File - 51K, Inhibition of VEGFR2 phosphorylation in vivo.
Supplementary Figure 4 from A Novel Inhibitor of c-Met and VEGF Receptor Tyrosine Kinases with a Broad Spectrum of In Vivo Antitumor Activities
Authors: Awazu Yoshiko , Nakamura Kazuhide , Mizutani Akio , Kakoi Yuichi , Iwata Hidehisa , Yamasaki Seiji , Miyamoto Naoki , Imamura Shinichi , Miki Hiroshi , Hori Akira
Published: April 2023

PDF File - 65K, Pharmacokinetic analysis of T-1840383.
Supplementary Figure 5 from Enhancement of Nab-Paclitaxel Antitumor Activity through Addition of Multitargeting Antiangiogenic Agents in Experimental Pancreatic Cancer
Authors: Awasthi Niranjan , Zhang Changhua , Schwarz Anna M. , Hinz Stefan , Schwarz Margaret A. , Schwarz Roderich E.
Published: April 2023

PDF - 231K, Tumor tissue sections were stained with collagen-1 antibody and slides were photographed under a fluorescent microscope. Collagen-1 pixel intensity was calculated and represented as bar graph. The data are expressed as the mean (plus or minus) standard deviation. Symbol * represents p<0.005 versus control, and ⋅ represents p<0.03 versus NPT.
Supplementary Figure 4 from Enhancement of Nab-Paclitaxel Antitumor Activity through Addition of Multitargeting Antiangiogenic Agents in Experimental Pancreatic Cancer
Authors: Awasthi Niranjan , Zhang Changhua , Schwarz Anna M. , Hinz Stefan , Schwarz Margaret A. , Schwarz Roderich E.
Published: April 2023

PDF - 128K, Tumor lysates were analyzed by immunoblotting for p-stathmin, alpha-tubulin and GAPDH proteins. Data are representative of two independent experiments with similar results.
Supplementary Figure 2 from Enhancement of Nab-Paclitaxel Antitumor Activity through Addition of Multitargeting Antiangiogenic Agents in Experimental Pancreatic Cancer
Authors: Awasthi Niranjan , Zhang Changhua , Schwarz Anna M. , Hinz Stefan , Schwarz Margaret A. , Schwarz Roderich E.
Published: April 2023

PDF - 103K, Nude mice were subcutaneously injected with AsPC-1 cells and treated for 3 weeks. Mean tumor weight was calculated from final day tumor weights in each group and is presented as Box plot. Data are representative of mean values (plus or minus) standard deviation from 6-8 mice per group.
Supplementary Figure 5 from Metabolomics Identifies Pyrimidine Starvation as the Mechanism of 5-Aminoimidazole-4-Carboxamide-1-β-Riboside-Induced Apoptosis in Multiple Myeloma Cells
Authors: Bardeleben Carolyne , Sharma Sanjai , Reeve Joseph R. , Bassilian Sara , Frost Patrick , Hoang Bao , Shi Yijiang , Lichtenstein Alan
Published: April 2023

PDF file - 82K, Cell cycle analysis of cells treated with AICAr in the presence or absence of uridine.
Supplementary Figure 1 from Metabolomics Identifies Pyrimidine Starvation as the Mechanism of 5-Aminoimidazole-4-Carboxamide-1-β-Riboside-Induced Apoptosis in Multiple Myeloma Cells
Authors: Bardeleben Carolyne , Sharma Sanjai , Reeve Joseph R. , Bassilian Sara , Frost Patrick , Hoang Bao , Shi Yijiang , Lichtenstein Alan
Published: April 2023

PDF file - 64K, Chemical structure of bortezomib, melphalan and metformin.
Supplementary Table 2 from A Novel Human Dynactin-Associated Protein, dynAP, Promotes Activation of Akt, and Ergosterol-Related Compounds Induce dynAP-Dependent Apoptosis of Human Cancer Cells
Authors: Kunoh Tatsuki , Noda Takanori , Koseki Koichi , Sekigawa Masayuki , Takagi Motoki , Shin-ya Kazuo , Goshima Naoki , Iemura Shun-ichiro , Natsume Tohru , Wada Shu-ichi , Mukai Yukio , Ohta Shinji , Sasaki Ryuzo , Mizukami Tamio
Published: April 2023

Supplementary Table 2 from A Novel Human Dynactin-Associated Protein, dynAP, Promotes Activation of Akt, and Ergosterol-Related Compounds Induce dynAP-Dependent Apoptosis of Human Cancer Cells
Supplementary Figures 1 through 6, Supplementary Tables 2 and 2, and Supplementary Methods from Selective Inhibition of Pancreatic Ductal Adenocarcinoma Cell Growth by the Mitotic MPS1 Kinase Inhibitor NMS-P715
Authors: Slee Roger B. , Grimes Brenda R. , Bansal Ruchi , Gore Jesse , Blackburn Corinne , Brown Lyndsey , Gasaway Rachel , Jeong Jaesik , Victorino Jose , March Keith L. , Colombo Riccardo , Herbert Brittney-Shea , Korc Murray
Published: April 2023

PDF - 1019K, Figure S1 The CIN70 signature predicts survival in PDAC patients. Figure S2 Murine PDAC KRC cells exhibit chromosome instability and evidence of a weakened SAC. Figure S3 Clonogenic survival of PANC-1 and BxPC3 cells treated with NMS-P715. Figure S4 Growth of human adipose stem cells (ASCs) in the presence of NMS-P715. Figure S5 Murine PDAC KRC cell growth is inhibited by NMS-P715. Figure S6 Inhibition of PDAC cell growth after pre-treatment with NMS-P715. Table S1 Chromosome stability in cell lines. Table S2 PDAC CIN25 genes ranked by Cox score Supplementary methods for gene expression and survival analyses.
Supplementary Table 1 from A Novel Human Dynactin-Associated Protein, dynAP, Promotes Activation of Akt, and Ergosterol-Related Compounds Induce dynAP-Dependent Apoptosis of Human Cancer Cells
Authors: Kunoh Tatsuki , Noda Takanori , Koseki Koichi , Sekigawa Masayuki , Takagi Motoki , Shin-ya Kazuo , Goshima Naoki , Iemura Shun-ichiro , Natsume Tohru , Wada Shu-ichi , Mukai Yukio , Ohta Shinji , Sasaki Ryuzo , Mizukami Tamio
Published: April 2023

Supplementary Table 1 from A Novel Human Dynactin-Associated Protein, dynAP, Promotes Activation of Akt, and Ergosterol-Related Compounds Induce dynAP-Dependent Apoptosis of Human Cancer Cells
Supplementary Figure Legends from A Novel Human Dynactin-Associated Protein, dynAP, Promotes Activation of Akt, and Ergosterol-Related Compounds Induce dynAP-Dependent Apoptosis of Human Cancer Cells
Authors: Kunoh Tatsuki , Noda Takanori , Koseki Koichi , Sekigawa Masayuki , Takagi Motoki , Shin-ya Kazuo , Goshima Naoki , Iemura Shun-ichiro , Natsume Tohru , Wada Shu-ichi , Mukai Yukio , Ohta Shinji , Sasaki Ryuzo , Mizukami Tamio
Published: April 2023

Supplementary Figure Legends from A Novel Human Dynactin-Associated Protein, dynAP, Promotes Activation of Akt, and Ergosterol-Related Compounds Induce dynAP-Dependent Apoptosis of Human Cancer Cells
Supplementary Methods, Figures 1 - 7 from Antitumor Impact of p14ARF on Gefitinib-Resistant Non–Small Cell Lung Cancers
Authors: Saito Ken , Takigawa Nagio , Ohtani Naoko , Iioka Hidekazu , Tomita Yuki , Ueda Ryuzo , Fukuoka Junya , Kuwahara Kazuhiko , Ichihara Eiki , Kiura Katsuyuki , Kondo Eisaku
Published: April 2023

PDF file - 1361K, Supplementary Figure 1: Cell cycle regulation and gene expression by gefitinib in the NSCLC. Supplementary Figure 2: p16INK4a and p14ARF expressions in response to gefitinib. Supplementary Figure 3: Regulation of p14ARF by chemotherapetic drugs. Supplementary Figure 4: Mutations of p16INK4a, p14ARF and p53 in the NSCLC cells. Supplementary Figure 5: Subcellular localization of the truncated GFP-p14ARF fusion proteins. Supplementary Figure 6: Growth suppression of the tumor cells by various anti-tumor peptides. Supplementary Figure 7: Immunohistochemistry of p14ARF and p53 in the NSCLC tissues. cells.
Supplementary Table 6 from Genome-wide siRNA Screen Identifies the Radiosensitizing Effect of Downregulation of MASTL and FOXM1 in NSCLC
Authors: Nagel Remco , Stigter-van Walsum Marijke , Buijze Marijke , van den Berg Jaap , van der Meulen Ida H. , Hodzic Jasmina , Piersma Sander R. , Pham Thang V. , Jiménez Connie R. , van Beusechem Victor W. , Brakenhoff Ruud H.
Published: April 2023

Supplementary Table 6. Cell cycle cluster obtained from DAVID analysis on proteins that are less phosphorylated in SW1573 shMASTL cells upon radiation.
Supplementary Figure 3 from A Novel Human Dynactin-Associated Protein, dynAP, Promotes Activation of Akt, and Ergosterol-Related Compounds Induce dynAP-Dependent Apoptosis of Human Cancer Cells
Authors: Kunoh Tatsuki , Noda Takanori , Koseki Koichi , Sekigawa Masayuki , Takagi Motoki , Shin-ya Kazuo , Goshima Naoki , Iemura Shun-ichiro , Natsume Tohru , Wada Shu-ichi , Mukai Yukio , Ohta Shinji , Sasaki Ryuzo , Mizukami Tamio
Published: April 2023

Supplementary Figure 3 from A Novel Human Dynactin-Associated Protein, dynAP, Promotes Activation of Akt, and Ergosterol-Related Compounds Induce dynAP-Dependent Apoptosis of Human Cancer Cells
Supplementary Figure Legends from Genome-wide siRNA Screen Identifies the Radiosensitizing Effect of Downregulation of MASTL and FOXM1 in NSCLC
Authors: Nagel Remco , Stigter-van Walsum Marijke , Buijze Marijke , van den Berg Jaap , van der Meulen Ida H. , Hodzic Jasmina , Piersma Sander R. , Pham Thang V. , Jiménez Connie R. , van Beusechem Victor W. , Brakenhoff Ruud H.
Published: April 2023

Supplementary Figure Legends. Legends to the Supplementary Figures
Supplementary Figure 3 from Genome-wide siRNA Screen Identifies the Radiosensitizing Effect of Downregulation of MASTL and FOXM1 in NSCLC
Authors: Nagel Remco , Stigter-van Walsum Marijke , Buijze Marijke , van den Berg Jaap , van der Meulen Ida H. , Hodzic Jasmina , Piersma Sander R. , Pham Thang V. , Jiménez Connie R. , van Beusechem Victor W. , Brakenhoff Ruud H.
Published: April 2023

Supplementary Figure 3. MASTL knockdown in A549 cells.
Supplementary Figure 6 from MCL-1 Degradation Mediated by JNK Activation via MEKK1/TAK1-MKK4 Contributes to Anticancer Activity of New Tubulin Inhibitor MT189
Authors: Wang Wei , Wang Ying-Qing , Meng Tao , Yi Jun-Mei , Huan Xia-Juan , Ma Lan-Ping , Tong Lin-Jiang , Chen Yi , Ding Jian , Shen Jing-Kang , Miao Ze-Hong
Published: April 2023

PDF - 22K, The effects of MT189 on the levels of cellular MCL-1 mRNA.
Supplementary Figure 5 from MCL-1 Degradation Mediated by JNK Activation via MEKK1/TAK1-MKK4 Contributes to Anticancer Activity of New Tubulin Inhibitor MT189
Authors: Wang Wei , Wang Ying-Qing , Meng Tao , Yi Jun-Mei , Huan Xia-Juan , Ma Lan-Ping , Tong Lin-Jiang , Chen Yi , Ding Jian , Shen Jing-Kang , Miao Ze-Hong
Published: April 2023

PDF - 44K, MT189 changes the levels of MCL-1 protein and induces apoptosis.
Supplementary Figure 4 from Novel ATP-Competitive MEK Inhibitor E6201 Is Effective against Vemurafenib-Resistant Melanoma Harboring the MEK1-C121S Mutation in a Preclinical Model
Authors: Narita Yusuke , Okamoto Kiyoshi , Kawada Megumi Ikemori , Takase Kazuma , Minoshima Yukinori , Kodama Kotaro , Iwata Masao , Miyamoto Norimasa , Sawada Kohei
Published: April 2023

PDF - 86K, Cleavaged -PARP induction in A375 and G361 parental cells.
Supplementary Figure 2 from MCL-1 Degradation Mediated by JNK Activation via MEKK1/TAK1-MKK4 Contributes to Anticancer Activity of New Tubulin Inhibitor MT189
Authors: Wang Wei , Wang Ying-Qing , Meng Tao , Yi Jun-Mei , Huan Xia-Juan , Ma Lan-Ping , Tong Lin-Jiang , Chen Yi , Ding Jian , Shen Jing-Kang , Miao Ze-Hong
Published: April 2023

PDF - 21K, MT189 displays an enhanced in vitro proliferation-inhibitory activity when compared with its parental compound MT119.
Supplementary Methods, Table 1 from Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity
Authors: Campbell Robert M. , Anderson Bryan D. , Brooks Nathan A. , Brooks Harold B. , Chan Edward M. , De Dios Alfonso , Gilmour Raymond , Graff Jeremy R. , Jambrina Enrique , Mader Mary , McCann Denis , Na Songqing , Parsons Stephen H. , Pratt Susan E. , Shih Chuan , Stancato Louis F. , Starling James J. , Tate Courtney , Velasco Juan A. , Wang Yong , Ye Xiang S.
Published: April 2023

PDF file - 86K, Supplemental Table 1. Kinases where LY2228820 shows >1000-fold selectivity in vitro (p38 MAPK vs. other kinase).
Supplementary Tables 1 through 3 from Effective Targeting of Estrogen Receptor–Negative Breast Cancers with the Protein Kinase D Inhibitor CRT0066101
Authors: Borges Sahra , Perez Edith A. , Thompson E. Aubrey , Radisky Derek C. , Geiger Xochiquetzal J. , Storz Peter
Published: April 2023

Supplemental Table S1 shows differential expression of PRKD3 in breast cancer (triple negative vs triple positive); Supplemental Table S2 shows the differential expression of PRKD3 in breast cancer by ER status; and Supplemental Table S3 shows the level of PRKD1, PRKD2 and PRKD3 expression in invasive breast cancer cell lines according to their hormone receptor status. The file also contains the references for Tables S1 and S2.
Supplementary Figures S1 to S13 from Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors
Authors: Whittaker Steven R. , Cowley Glenn S. , Wagner Steve , Luo Flora , Root David E. , Garraway Levi A.
Published: April 2023

Figure S1: Following BRAF inhibition, recovery of ERK phosphorylation is observed and RKO cells continue to proliferate in the presence of PLX4720. Figure S2: DAPPLE analysis of the top 300 candidate genes from the primary screen identifies potential protein interaction networks. Figure S3: Knockdown of candidate genes sensitises cells to BRAF inhibition. Figure S4: Inhibition of MET is synergistic with PLX4720. Figure S5: Inhibition of SHP2 sensitises to PLX4720. Figure S6: Combinations of PLX4720 and AZD6244 are not synergistic. Figure S7: Cells displaying acquired resistance to PLX4720 are sensitive to combined pan-RAF and MEK inhibition. Figure S8: The combination of AZD6244 and RAF265 is synergistic. Figure S9: The combination of AZD6244 and MLN2480 is synergistic. Figure S10: The combination of GSK1120212 and AZ628 is synergistic. Figure S11: AZ628 shows greater synergy when combined with a MEK inhibitor than GSK2118436. Figure S12: Synergy between pan-RAF and MEK inhibition is rescued by a resistant allele of MEK. Figure S13: Pan-RAF and MEK inhibition results in decreased cell viability.
Data Supplement from Quinacrine Overcomes Resistance to Erlotinib by Inhibiting FACT, NF-κB, and Cell-Cycle Progression in Non–Small Cell Lung Cancer
Authors: Dermawan Josephine Kam Tai , Gurova Katerina , Pink John , Dowlati Afshin , De Sarmishtha , Narla Goutham , Sharma Neelesh , Stark George R.
Published: April 2023

Supplementary Table 1 and Table 2
Data Supplement from Quinacrine Overcomes Resistance to Erlotinib by Inhibiting FACT, NF-κB, and Cell-Cycle Progression in Non–Small Cell Lung Cancer
Authors: Dermawan Josephine Kam Tai , Gurova Katerina , Pink John , Dowlati Afshin , De Sarmishtha , Narla Goutham , Sharma Neelesh , Stark George R.
Published: April 2023

Legends for Supplementary Tables 1,2 and Figures S1-S3
Supplemental Table2 from Sarcoma Cell Line Screen of Oncology Drugs and Investigational Agents Identifies Patterns Associated with Gene and microRNA Expression
Authors: Teicher Beverly A. , Polley Eric , Kunkel Mark , Evans David , Silvers Thomas , Delosh Rene , Laudeman Julie , Ogle Chad , Reinhart Russell , Selby Michael , Connelly John , Harris Erik , Monks Anne , Morris Joel
Published: April 2023

Table of compounds that were in the screen.
Supplemental figure 1 from Antiandrogen Therapy with Hydroxyflutamide or Androgen Receptor Degradation Enhancer ASC-J9 Enhances BCG Efficacy to Better Suppress Bladder Cancer Progression
Authors: Shang Zhiqun , Li Yanjun , Zhang Minghao , Tian Jing , Han Ruifa , Shyr Chih-Rong , Messing Edward , Yeh Shuyuan , Niu Yuanjie , Chang Chawnshang
Published: April 2023

Supplemental figure 1 ASC-J9® degraded androgen receptor expression in bladder cancer
Supplementary TableS2 from Mechanism of Oncogenic Signal Activation by the Novel Fusion Kinase FGFR3–BAIAP2L1
Authors: Nakanishi Yoshito , Akiyama Nukinori , Tsukaguchi Toshiyuki , Fujii Toshihiko , Satoh Yasuko , Ishii Nobuya , Aoki Masahiro
Published: April 2023

Sensitivity of FGFR inhibitors against cells harboring FGFR3-BAIAP2L1
Supplementary Table S1 and Supplementary Figure Legends from The CDK4/6 Inhibitor LY2835219 Overcomes Vemurafenib Resistance Resulting from MAPK Reactivation and Cyclin D1 Upregulation
Authors: Yadav Vipin , Burke Teresa F. , Huber Lysiane , Van Horn Robert D. , Zhang Youyan , Buchanan Sean G. , Chan Edward M. , Starling James J. , Beckmann Richard P. , Peng Sheng-Bin
Published: April 2023

Supplementary table S1 describes the copy number variations in A375-R1 and A375 parental cells. Supplementary figure legends describe supplementary figures S1-3.
Supplementary Figures S1-S4 from The CDK4/6 Inhibitor LY2835219 Overcomes Vemurafenib Resistance Resulting from MAPK Reactivation and Cyclin D1 Upregulation
Authors: Yadav Vipin , Burke Teresa F. , Huber Lysiane , Van Horn Robert D. , Zhang Youyan , Buchanan Sean G. , Chan Edward M. , Starling James J. , Beckmann Richard P. , Peng Sheng-Bin
Published: April 2023

Supplementary figure S1 describes the molecular mechanisms of resistance across vemurafenib-resistant cell line models. Supplementary figure S2 serves as a repeat of figure 3a describing development of in vivo model of resistance, and demonstrates the effect of vemurafenib withdrawl on the resistant tumors. Supplementary figure S3 describes the effect of vemurafenib treatment on MAPK pathway inhibition in A375-RV2 cells. Supplementary figure S4 shows that selective cyclin D1 knockdown or CDK4/6 inhibition induces apoptosis in A375-R1 and M14-R vemurafenib-resistant melanoma cells.
Supplementary Figure S4 from Mechanism of Oncogenic Signal Activation by the Novel Fusion Kinase FGFR3–BAIAP2L1
Authors: Nakanishi Yoshito , Akiyama Nukinori , Tsukaguchi Toshiyuki , Fujii Toshihiko , Satoh Yasuko , Ishii Nobuya , Aoki Masahiro
Published: April 2023

Pathway analysis of FGFR3-BAIAP2L1
Supplementary Figure S3 from Mechanism of Oncogenic Signal Activation by the Novel Fusion Kinase FGFR3–BAIAP2L1
Authors: Nakanishi Yoshito , Akiyama Nukinori , Tsukaguchi Toshiyuki , Fujii Toshihiko , Satoh Yasuko , Ishii Nobuya , Aoki Masahiro
Published: April 2023

Effects of CH5183284/Debio 1347 or siRNAs on FGFR3-BAIAP2L1 positive cells
Supplementary Materials and Methods, Supplementary Tables 1 through 4, and Supplementary Figures 1 through 9 from Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2
Authors: Smith Bryan D. , Kaufman Michael D. , Leary Cynthia B. , Turner Benjamin A. , Wise Scott C. , Ahn Yu Mi , Booth R. John , Caldwell Timothy M. , Ensinger Carol L. , Hood Molly M. , Lu Wei-Ping , Patt Tristan W. , Patt William C. , Rutkoski Thomas J. , Samarakoon Thiwanka , Telikepalli Hanumaiah , Vogeti Lakshminarayana , Vogeti Subha , Yates Karen M. , Chun Lawrence , Stewart Lance J. , Clare Michael , Flynn Daniel L.
Published: April 2023

Supplementary Materials and Methods. Supplementary table 1: XRay crystallography parameters for DP-4157/MET complex. Supplementary table 2: Source and description of kinases. Supplementary table 3: Selectivity of profile of altiratinib inhibition from Reaction Biology 295 kinase panel (fold selectivity versus IC50 value of 2.7 nM MET inhibition). Supplementary table 4: A. Inhibition of MET phosphorylation in the MKN-45 xenograft model after a single oral dose of altiratinib (30 mg/kg); B. Inhibition of MET phosphorylation in the MKN-45 xenograft model after a single oral dose of altiratinib (10 mg/kg). Supplementary figure 1: Co-crystal structures of altiratinib analog DP-4157. Supplementary figure 2: Comparison of altiratinib with other clinical stage MET inhibitors regarding potency versus activation loop mutant forms D1228H, D1228N, Y1230D, Y1230C, and Y1230H. Supplementary figure 3: Determination of off-rate, residency time, and tight-binding inhibitor constant Kd for altiratinib binding to the MET kinase domain. Supplementary figure 4: Michaelis-Menton analysis of altiratinib inhibition of MET with respect to ATP. Supplementary figure 5: Kinome tree interaction profile for altiratinib vs 295 human kinases. Altiratinib was evaluated using Kinase HotspotSM platform from Reaction Biology (Malvern, PA). Supplementary figure 6: Inhibitory potencies for inhibiting HUVEC cell signaling activated by HGF/MET (black), VEGF-A/VEGFR2 (melon), and ANG2/TIE2 (tan). Comparative potencies are shown for altiratinib, E-7050, cabozantinib, and MGCD-265. Supplementary figure 7: Upper panel: inhibition of capillary tube formation by various concentrations of altiratinib. Tube formation was initiated by addition of 200 ng/mL of angiopoietin 2 (ANG2). Lower table: titrated IC50 values for inhibition of capillary tube formation induced by ANG2, HGF, and VEGF-A. Supplementary figure 8: Inhibition of proliferation in the mutant B-RAF melanoma SK-MEL-28 cell line in the absence or presence of HGF or MRC-5 fibroblast conditioned medium. Supplementary figure 9: Ratio of brain: plasma concentrations of altiratinib through 24 hr after administration of a single dose of 5 mg/kg IV to C57/Black mice.
Supplementary figure 1 from Long Noncoding RNA ANRIL Promotes Non–Small Cell Lung Cancer Cell Proliferation and Inhibits Apoptosis by Silencing KLF2 and P21 Expression
Authors: Nie Feng-qi , Sun Ming , Yang Jin-song , Xie Min , Xu Tong-peng , Xia Rui , Liu Yan-wen , Liu Xiang-hua , Zhang Er-bao , Lu Kai-hua , Shu Yong-qian
Published: April 2023

Supplementary figure 1. The effect of ANRIL on cells proliferation and migration
Supplementary Table S2 from Triple-Negative Breast Cancer Patients Treated at MD Anderson Cancer Center in Phase I Trials: Improved Outcomes with Combination Chemotherapy and Targeted Agents
Authors: Ganesan Prasanth , Moulder Stacy , Lee J. Jack , Janku Filip , Valero Vicente , Zinner Ralph G. , Naing Aung , Fu Siqing , Tsimberidou Apostolia M. , Hong David , Stephen Bettzy , Stephens Philip , Yelensky Roman , Meric-Bernstam Funda , Kurzrock Razelle , Wheler Jennifer J.
Published: April 2023

Supplementary Table S2. Univariate analysis of factors affecting Response, PFS, and, OS in first phase I therapy
Supplementary Figure 5 from Cambogin Induces Caspase-Independent Apoptosis through the ROS/JNK Pathway and Epigenetic Regulation in Breast Cancer Cells
Authors: Shen Kaikai , Xie Jianling , Wang Hua , Zhang Hong , Yu Mengyuan , Lu Fangfang , Tan Hongsheng , Xu Hongxi
Published: April 2023

Supplementary Figure 5. We have shown here that in MCF-7, MDA-MB-468, and SK-BR-3 cells, the pro-apoptotic effects of cambogin were prevented by antioxidative enzymes (CAT and SOD), further supporting the notion that ROS production is responsible for cambogin-induced cell death.
Data Supplement from EpCAM-Selective Elimination of Carcinoma Cells by a Novel MAP-Based Cytolytic Fusion Protein
Authors: Hristodorov Dmitrij , Amoury Manal , Mladenov Radoslav , Niesen Judith , Arens Katharina , Berges Nina , Hein Lea , Di Fiore Stefano , Pham Anh-Tuan , Huhn Michael , Helfrich Wijnand , Fischer Rainer , Thepen Theo , Barth Stefan
Published: April 2023

Supplementary Figure 1. Cell-binding activity of anti-EpCAM(scFv)-MAP to further target cell lines.
Supplementary Figure 2 from Cambogin Induces Caspase-Independent Apoptosis through the ROS/JNK Pathway and Epigenetic Regulation in Breast Cancer Cells
Authors: Shen Kaikai , Xie Jianling , Wang Hua , Zhang Hong , Yu Mengyuan , Lu Fangfang , Tan Hongsheng , Xu Hongxi
Published: April 2023

Supplementary Figure 2. Related to Fig. 2, the caspase-independent mitochondrial apoptotic pathway was also activated in response to cambogin in MDA-MB-468 and SK-BR-3 cells, similar to MCF-7 cells tested in Fig. 2.
Supplementary Table 5 from Pharmacological Profiling of Kinase Dependency in Cell Lines across Triple-Negative Breast Cancer Subtypes
Authors: Fink Lauren S. , Beatty Alexander , Devarajan Karthik , Peri Suraj , Peterson Jeffrey R.
Published: April 2023

Supplementary Table 5: EC50 values (microM) for PI3K pathway-targeting agents tested in 12 TNBC cell lines.
Supplementary Table 3 from Pharmacological Profiling of Kinase Dependency in Cell Lines across Triple-Negative Breast Cancer Subtypes
Authors: Fink Lauren S. , Beatty Alexander , Devarajan Karthik , Peri Suraj , Peterson Jeffrey R.
Published: April 2023

Supplementary Table 3: EC50 values (microM) for EGFR-targeting agents tested in 12 TNBC cell lines.
Supplementary legend from Selective Nuclear Export Inhibitor KPT-330 Enhances the Antitumor Activity of Gemcitabine in Human Pancreatic Cancer
Authors: Kazim Sabiha , Malafa Mokenge P. , Coppola Domenico , Husain Kazim , Zibadi Sherma , Kashyap Trinayan , Crochiere Marsha , Landesman Yosef , Rashal Tami , Sullivan Daniel M. , Mahipal Amit
Published: April 2023

Supplemental legend for Fig. S1
Supplementary Table 1 from Pharmacological Profiling of Kinase Dependency in Cell Lines across Triple-Negative Breast Cancer Subtypes
Authors: Fink Lauren S. , Beatty Alexander , Devarajan Karthik , Peri Suraj , Peterson Jeffrey R.
Published: April 2023

Supplementary Table 1: Complete kinase inhibitor screening dataset for 12 TNBC cell lines.
Supplementary Figure 3 from Pharmacological Profiling of Kinase Dependency in Cell Lines across Triple-Negative Breast Cancer Subtypes
Authors: Fink Lauren S. , Beatty Alexander , Devarajan Karthik , Peri Suraj , Peterson Jeffrey R.
Published: April 2023

Supplementary Figure 3: Kinase inhibitors showing selective toxicity for Group 1 cell lines. Dot-plots showing response of Groups 1, 2, and 3 cell lines to additional kinase inhibitors with selective toxicity for Group 1. Black lines indicate mean EC50 for each group. Group 1 selectivity is shown for inhibitors with p < 0.05, and inhibitors are displayed by increasing p value.
Supplementary Figures 1 through 15 and Supplementary Table 1 from Drug Repurposing Identifies a Synergistic Combination Therapy with Imatinib Mesylate for Gastrointestinal Stromal Tumor
Authors: Pessetto Ziyan Y. , Ma Yan , Hirst Jeff J. , von Mehren Margaret , Weir Scott J. , Godwin Andrew K.
Published: April 2023

Figure S1. Analysis of combination index (CI) value of IM combined with FDA-approved drugs in GIST-T1 cells. Figure S2. Analysis of CI value of IM combined with FDA-approved drugs in GIST 882 cells. Figure S3. Analysis of CI value of IM combined with FDA-approved drugs in GIST T1-10R cells. Figure S4. Drug combination assays using the checkerboard experimental design. Figure S5. Representative dose-effect, median-effect and normalized isobologram (Chou-Chou Plot) plots for IM in combination with idarubicin on A) GIST-T1, B) GIST 882, and C) GIST T1-10R cells. Figure S6. Representative dose-effect, median-effect and normalized isobologram (Chou-Chou Plot) plots for IM in combination with digoxin on A) GIST-T1, B) GIST 882, and C) GIST T1-10R cells. Figure S7. Representative dose-effect, median-effect and normalized isobologram (Chou-Chou Plot) plots for IM in combination with bortezomib on A) GIST-T1, B) GIST 882, and C) GIST T1-10R cells. Figure S8. Representative dose-effect, median-effect and normalized isobologram (Chou-Chou Plot) plots for IM in combination with auranofin on A) GIST-T1, B) GIST 882, and C) GIST T1-10R cells. Figure S9. Representative dose-effect, median-effect and normalized isobologram (Chou-Chou Plot) plots for IM in combination with ouabain on A) GIST-T1, B) GIST 882, and C) GIST T1-10R cells. Figure S10. Representative dose-effect, median-effect and normalized isobologram (Chou-Chou Plot) plots for IM in combination with gentian violet on A) GIST-T1, B) GIST 882, and C) GIST T1-10R cells. Figure S11. Representative dose-effect, median-effect and normalized isobologram (Chou-Chou Plot) plots for IM in combination with carbimazole on A) GIST-T1, B) GIST 882, and C) GIST T1-10R cells. Figure S12. Representative dose-effect, median-effect and normalized isobologram (Chou-Chou Plot) plots for IM in combination with F-AMP on A) GIST-T1, B) GIST 882, and C) GIST T1-10R cells. Figure S13. Apoptosis analysis of GIST cells treated with vehicle, F-AMP, IM, or the drug combination. Figure S14. Mice body weights of each treatment group in the in vivo study. Figure S15. Representative H and E staining photographs of livers, kidneys and spleens from each treatment group in the in vivo study. Table S1. Optimized drug doses for the apoptosis assays.
Supplementary table 1 from Targeting the Nuclear Import Receptor Kpnβ1 as an Anticancer Therapeutic
Authors: van der Watt Pauline J. , Chi Alicia , Stelma Tamara , Stowell Catherine , Strydom Erin , Carden Sarah , Angus Liselotte , Hadley Kate , Lang Dirk , Wei Wei , Birrer Michael J. , Trent John O. , Leaner Virna D.
Published: April 2023

Chemical compounds identified in the in silico screen that display IC50 values of less than 50uM.
Supplementary figure 2 from Targeting the Nuclear Import Receptor Kpnβ1 as an Anticancer Therapeutic
Authors: van der Watt Pauline J. , Chi Alicia , Stelma Tamara , Stowell Catherine , Strydom Erin , Carden Sarah , Angus Liselotte , Hadley Kate , Lang Dirk , Wei Wei , Birrer Michael J. , Trent John O. , Leaner Virna D.
Published: April 2023

SubG1 cell populations after INI-43 treatment of CaSki cells for 6 and 24 hr.
Supplementary figure 1 from Targeting the Nuclear Import Receptor Kpnβ1 as an Anticancer Therapeutic
Authors: van der Watt Pauline J. , Chi Alicia , Stelma Tamara , Stowell Catherine , Strydom Erin , Carden Sarah , Angus Liselotte , Hadley Kate , Lang Dirk , Wei Wei , Birrer Michael J. , Trent John O. , Leaner Virna D.
Published: April 2023

Dose-response curves showing cell line responses to INI-43 treatment.
Data Supplement from Calpain-Mediated Integrin Deregulation as a Novel Mode of Action for the Anticancer Gallium Compound KP46
Authors: Jungwirth Ute , Gojo Johannes , Tuder Theresa , Walko Gernot , Holcmann Martin , Schöfl Thomas , Nowikovsky Karin , Wilfinger Nastasia , Schoonhoven Sushilla , Kowol Christian R. , Lemmens-Gruber Rosa , Heffeter Petra , Keppler Bernhard K. , Berger Walter
Published: April 2023

Supplementary Figure 1. Role of p53 status and mitochondrial membrane depolarization in KP46-induced cell death Supplementary Figure 2. Expression and localization changes of pro- and anti-apoptotic Bcl-2 family members in response to KP46 treatment Supplementary Figure 3. Impact or KP46 on integrin ÃŽÂ²1 expression and subcellular localization in cancer cells Supplementary Figure 4. Alteration in intracellular Ca2+ levels in HCT-116 cells upon KP46 treatment Supplementary Figure 5 Effect of extracellular calpain inhibition on KP46 sensitivity in A427 and HCT-116 cells
Supplementary Figures S1-S3 from Small Molecule BMH-Compounds That Inhibit RNA Polymerase I and Cause Nucleolar Stress
Authors: Peltonen Karita , Colis Laureen , Liu Hester , Jäämaa Sari , Zhang Zhewei , af Hällström Taija , Moore Henna M. , Sirajuddin Paul , Laiho Marikki
Published: April 2023

Supplementary Figures S1-S3. Supplementary Figure 1. BMH-9, BMH-22 and BMH-23 cause a reduction in RPA194 half life. Supplementary Figure 2. BMH-9, BMH-22 and BMH-23 do not activate the DNA damage response. Supplementary Figure 3. p53 activation by Nutlin-3 does not affect the integrity of the nucleolus or rRNA synthesis.